Business
New Stem Cell Collection Service
New Stem Cell Collection Service.
About this update from Ilika Plc
[{"type":"text","content":"\n \nRNS Number : 8857H Ilika plc 06 June 2011 \n \n\n \n \n6 June 2011\nIlika plc\n \nAltrika participates in development of new Stem Cell Collection Service, Oristem®\n \nIlika plc is pleased to announce the involvement of Altrika Ltd, its wholly owned subsidiary, in the Oristem® stem cell bank, a significant new medical breakthrough involving the collection and storage of stem cells from adults. \nThe Oristem® service has been developed through a partnership between Altrika, Pharmacells Limited and Vindon Scientific Limited. Pharmacells has licensed a new, patented method of harvesting, isolating and storing stem cells derived from adult blood. Vindon is a recognised leader in temperature and humidity controlled storage and its state of the art storage facility for human tissue and cells will aid both Altrika and Oristem® in this new and exciting field.\nAltrika is a cell therapeutics company specialising in the fields of wound treatment and skin regeneration. As one of the few commercial organisations with experience of both cell processing and advanced therapies, Altrika's involvement in this key step of the Oristem programme will ensure that the samples received from clients are handled with the greater care and processed to the level required for future use in treatment.\nPrevious forms of stem cell extraction had been confined to neo-natal stem cells taken from umbilical cords and immediately stored, or more invasive sources such as fat tissue or bone marrow. The concept of stem cells from adult blood is very new and represents an important development in the possible treatment of illnesses that adults may contract in the future.\nThe Oristem® product offers a customised stem cell collection system that enables adults to be visited at home for blood samples to be taken. A bespoke, temperature controlled collection kit is used and the blood samples are processed using the patented method, ultimately ending up with the frozen storage of two samples of multipotent adult stem cells. If a new stem cell based treatment for a particular disease has been developed, the client will have healthy, younger cells available to form the basis of a personalised, regenerative therapy or treatment. It thus represents a form of medical investment on the part of individuals wishi...